Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206375 · ClinicalTrials.gov registry record · Phase 4
Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
A Phase 4 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00206375: Clinical Trial Phase 4 study, sponsored by Baylor College of Medicine.
NCT00206375 is a Phase 4 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206375, a Phase 4 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.
Primary Outcome
The study was terminated due to insufficient funds. The study was terminated and the study PI has left the institution. All efforts to locate the study PI have been exhausted and the data is no longer available and cannot be reported.
Interventions
- DRUG Growth hormone
- DRUG Growth hormone treatment and puberty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Why NCT00206375 stopped before completion
NCT00206375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Growth hormone is the first listed.
NCT00206375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206375 about?
NCT00206375 is a clinical study titled "Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism". The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potent...
What is the current status of trial NCT00206375?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2003-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00206375?
The interventions under investigation include: Growth hormone (DRUG), Growth hormone treatment and puberty (DRUG).
Who is sponsoring clinical trial NCT00206375?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206375's enrollment target sits among peer trials
16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia